Stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumors: The RAPPORT trial.
Shankar Siva, Mathias Bressel, Simon Wood, Mark Shaw, Sherene Loi, Shahneen Kaur Sandhu, Ben Tran, Arun Azad, Jeremy Howard Lewin, Katharine Cuff, Nitika Neha, Duncan Colyer, Paul J Neeson, Howard Liu, Sarat Chander, Daniel Moon, Jeremy Goad, Declan G Murphy, Nathan Lawrentschuk, David Pryor
JOURNAL OF CLINICAL ONCOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2021
277 Background: Pembrolizumab monotherapy, whilst not standard of care, has demonstrated efficacy in clear cell renal cell carcinoma (ccRCC). The first-line KEYNOTE-427 study demonstrated an overall response rate (ORR) of 34%, and a median progression-free survival (PFS) of 7.1 mo (McDermott D et al. J Clin Oncol 2020; 38:S15; 5069-5069). Stereotactic ablative body radiotherapy (SABR) is an option for oligometastatic ccRCC, but patients often develop distant progression or relapse within irradiated sites. The RAPPORT study (NCT02855203) was a multi-institutional single arm, phase I/II study evaluating safety and efficacy of SABR and pembrolizumab. Methods: Patients with up to 2 lines of pri..View full abstract